Cite
1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
MLA
Planchard, D., et al. “1507TiP Phase Ib Multicenter Study of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy with or without Chemotherapy in First-Line Treatment of Patients (Pts) with Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and HER2 Overexpression (OE): DESTINY-Lung03.” Annals of Oncology, vol. 34, Oct. 2023, pp. S848–49. EBSCOhost, https://doi.org/10.1016/j.annonc.2023.09.2538.
APA
Planchard, D., Brahmer, J. R., Yang, J. .-H., Kim, H. R., Li, R. K., Han, J.-Y., Cortinovis, D. L., Runglodvatana, Y., Nakajima, E., Ragone, A., Winter, M., & Gustavson, M. (2023). 1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03. Annals of Oncology, 34, S848–S849. https://doi.org/10.1016/j.annonc.2023.09.2538
Chicago
Planchard, D., J.R. Brahmer, J.C-H. Yang, H.R. Kim, R.K. Li, J-Y. Han, D.L. Cortinovis, et al. 2023. “1507TiP Phase Ib Multicenter Study of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy with or without Chemotherapy in First-Line Treatment of Patients (Pts) with Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and HER2 Overexpression (OE): DESTINY-Lung03.” Annals of Oncology 34 (October): S848–49. doi:10.1016/j.annonc.2023.09.2538.